Severe Hypocalcemia and Dramatic Increase in Parathyroid Hormone after Denosumab in a Dialysis Patient: A Case Report and Review of the Literature

Chronic kidney disease-mineral and bone disorder (CKD-MBD) is frequently present in advanced stages of chronic kidney disease (CKD) patients with high risk of fracture and elevated socioeconomic burden. Denosumab, an injectable human monoclonal antibody with affinity for nuclear factor-kappa ligand...

Full description

Bibliographic Details
Main Authors: Ravinder D. Bhanot, Jasleen Kaur, Zeenat Bhat
Format: Article
Language:English
Published: Hindawi Limited 2019-01-01
Series:Case Reports in Nephrology
Online Access:http://dx.doi.org/10.1155/2019/3027419
id doaj-ca326f96be744109af500987ed81b6b2
record_format Article
spelling doaj-ca326f96be744109af500987ed81b6b22020-11-25T02:15:10ZengHindawi LimitedCase Reports in Nephrology2090-66412090-665X2019-01-01201910.1155/2019/30274193027419Severe Hypocalcemia and Dramatic Increase in Parathyroid Hormone after Denosumab in a Dialysis Patient: A Case Report and Review of the LiteratureRavinder D. Bhanot0Jasleen Kaur1Zeenat Bhat2Division of Pulmonary and Critical Care, St. Mary's of Michigan Medical Center, Saginaw, MI, USADepartment of Internal Medicine, Wayne State University, Detroit, MI, USADepartment of Internal Medicine, Wayne State University, Detroit, MI, USAChronic kidney disease-mineral and bone disorder (CKD-MBD) is frequently present in advanced stages of chronic kidney disease (CKD) patients with high risk of fracture and elevated socioeconomic burden. Denosumab, an injectable human monoclonal antibody with affinity for nuclear factor-kappa ligand (RANKL), is an effective treatment for osteoporosis in postmenopausal women and men. Unlike the bisphosphonates, the pharmacokinetics and pharmacodynamics of denosumab are not influenced by the renal function and are being increasingly used for patients having CKD-MBD with low bone mineral density (BMD) to reduce the risk of fragility fractures. Hypocalcemia is a known side effect of this drug along with compensatory increase in parathyroid hormone (PTH). However, limited information is available in the literature regarding this potentially life-threatening side effect with denosumab in end-stage renal disease (ESRD) patients on dialysis. We present a patient with ESRD on peritoneal dialysis who developed severe symptomatic hypocalcemia and dramatic increase in PTH following denosumab therapy. She was conservatively managed with calcium supplementation and appropriate adjustment in calcium dialysate. We have also reviewed the literature on the use of denosumab in dialysis patients and looked at additional factors that may precipitate severe hypocalcemia in these patients. We believe that denosumab should be used with caution in dialysis patients since it may lead to profound hypocalcemia. Clinicians should ensure special attention in recognizing patients at risk of developing this serious adverse effect, so that prompt treatment and preventive strategies can be implemented.http://dx.doi.org/10.1155/2019/3027419
collection DOAJ
language English
format Article
sources DOAJ
author Ravinder D. Bhanot
Jasleen Kaur
Zeenat Bhat
spellingShingle Ravinder D. Bhanot
Jasleen Kaur
Zeenat Bhat
Severe Hypocalcemia and Dramatic Increase in Parathyroid Hormone after Denosumab in a Dialysis Patient: A Case Report and Review of the Literature
Case Reports in Nephrology
author_facet Ravinder D. Bhanot
Jasleen Kaur
Zeenat Bhat
author_sort Ravinder D. Bhanot
title Severe Hypocalcemia and Dramatic Increase in Parathyroid Hormone after Denosumab in a Dialysis Patient: A Case Report and Review of the Literature
title_short Severe Hypocalcemia and Dramatic Increase in Parathyroid Hormone after Denosumab in a Dialysis Patient: A Case Report and Review of the Literature
title_full Severe Hypocalcemia and Dramatic Increase in Parathyroid Hormone after Denosumab in a Dialysis Patient: A Case Report and Review of the Literature
title_fullStr Severe Hypocalcemia and Dramatic Increase in Parathyroid Hormone after Denosumab in a Dialysis Patient: A Case Report and Review of the Literature
title_full_unstemmed Severe Hypocalcemia and Dramatic Increase in Parathyroid Hormone after Denosumab in a Dialysis Patient: A Case Report and Review of the Literature
title_sort severe hypocalcemia and dramatic increase in parathyroid hormone after denosumab in a dialysis patient: a case report and review of the literature
publisher Hindawi Limited
series Case Reports in Nephrology
issn 2090-6641
2090-665X
publishDate 2019-01-01
description Chronic kidney disease-mineral and bone disorder (CKD-MBD) is frequently present in advanced stages of chronic kidney disease (CKD) patients with high risk of fracture and elevated socioeconomic burden. Denosumab, an injectable human monoclonal antibody with affinity for nuclear factor-kappa ligand (RANKL), is an effective treatment for osteoporosis in postmenopausal women and men. Unlike the bisphosphonates, the pharmacokinetics and pharmacodynamics of denosumab are not influenced by the renal function and are being increasingly used for patients having CKD-MBD with low bone mineral density (BMD) to reduce the risk of fragility fractures. Hypocalcemia is a known side effect of this drug along with compensatory increase in parathyroid hormone (PTH). However, limited information is available in the literature regarding this potentially life-threatening side effect with denosumab in end-stage renal disease (ESRD) patients on dialysis. We present a patient with ESRD on peritoneal dialysis who developed severe symptomatic hypocalcemia and dramatic increase in PTH following denosumab therapy. She was conservatively managed with calcium supplementation and appropriate adjustment in calcium dialysate. We have also reviewed the literature on the use of denosumab in dialysis patients and looked at additional factors that may precipitate severe hypocalcemia in these patients. We believe that denosumab should be used with caution in dialysis patients since it may lead to profound hypocalcemia. Clinicians should ensure special attention in recognizing patients at risk of developing this serious adverse effect, so that prompt treatment and preventive strategies can be implemented.
url http://dx.doi.org/10.1155/2019/3027419
work_keys_str_mv AT ravinderdbhanot severehypocalcemiaanddramaticincreaseinparathyroidhormoneafterdenosumabinadialysispatientacasereportandreviewoftheliterature
AT jasleenkaur severehypocalcemiaanddramaticincreaseinparathyroidhormoneafterdenosumabinadialysispatientacasereportandreviewoftheliterature
AT zeenatbhat severehypocalcemiaanddramaticincreaseinparathyroidhormoneafterdenosumabinadialysispatientacasereportandreviewoftheliterature
_version_ 1724897400635523072